Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$12.50 -16.4%	$12.21	$3.61 ▼ $17.43	$847.75M	1.62	1.32 million shs	9.88 million shs
GHRS GH Research	$12.44 +0.3%	$11.37	$6.00 ▼ $20.50	$647.25M	0.97	192,565 shs	81,610 shs
KURA Kura Oncology	$5.67 -1.0%	$6.17	$5.41 ▼ $23.48	$490.85M	0.4	1.24 million shs	3.33 million shs
LRMR Larimar Therapeutics	$3.03 -1.6%	$2.41	$1.61 ▼ $11.20	$194.01M	0.79	836,795 shs	1.91 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	0.00%	-8.16%	+3.56%	+102.92%	+188.68%
GHRS GH Research	0.00%	+1.06%	+3.84%	+12.78%	+6.69%
KURA Kura Oncology	0.00%	-3.08%	-0.18%	-14.09%	-72.46%
LRMR Larimar Therapeutics	0.00%	+16.99%	+31.74%	+40.93%	-58.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	1.6058 of 5 stars	3.6	1.0	0.0	2.0	0.0	0.6
GHRS GH Research	1.6164 of 5 stars	3.5	1.0	0.0	2.7	0.8	0.0
KURA Kura Oncology	4.5249 of 5 stars	4.4	3.0	4.7	2.0	0.8	0.6
LRMR Larimar Therapeutics	1.8416 of 5 stars	3.6	1.0	0.0	2.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	3.17	Buy	$16.67	33.33% Upside
GHRS GH Research	3.00	Buy	$32.00	157.23% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	332.10% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	510.56% Upside

Current Analyst Ratings Breakdown

Latest LRMR, GHRS, KURA, and CRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	CRMD CorMedix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/23/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
6/20/2025	CRMD CorMedix	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$13.00 ➝ $17.00
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	19.50	N/A	N/A	$1.40 per share	8.93
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
KURA Kura Oncology	$53.88M	9.11	N/A	N/A	$5.32 per share	1.07
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.22	56.82	13.30	N/A	20.81%	22.57%	17.02%	8/13/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.79	N/A	N/A	N/A	N/A	-19.20%	-18.40%	9/2/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)

Latest LRMR, GHRS, KURA, and CRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GHRS GH Research	-$0.61	-$0.19	+$0.42	-$0.19	N/A	N/A
5/6/2025	Q1 2025	CRMD CorMedix	$0.25	$0.30	+$0.05	$0.30	$38.90 million	$39.08 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	4.21	3.99
GHRS GH Research	N/A	29.71	29.71
KURA Kura Oncology	0.02	8.07	8.07
LRMR Larimar Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
GHRS GH Research	56.90%
KURA Kura Oncology	N/A
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
GHRS GH Research	N/A
KURA Kura Oncology	6.40%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	67.82 million	64.23 million	Optionable
GHRS GH Research	10	52.03 million	N/A	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable

LRMR, GHRS, KURA, and CRMD Headlines

Recent News About These Companies

Wedbush Research Analysts Reduce Earnings Estimates for LRMR

June 28 at 2:07 AM | americanbankingnews.com

Research Analysts Issue Forecasts for LRMR FY2025 Earnings

June 27 at 2:07 AM | americanbankingnews.com

Research Analysts Issue Forecasts for LRMR Q2 Earnings

June 27 at 2:23 AM | americanbankingnews.com

Wedbush Predicts Reduced Earnings for Larimar Therapeutics

June 26, 2025 | marketbeat.com

What is Leerink Partnrs' Forecast for LRMR FY2026 Earnings?

June 26, 2025 | marketbeat.com

FY2025 Earnings Estimate for LRMR Issued By Lifesci Capital

June 26, 2025 | marketbeat.com

Wedbush Lowers Larimar Therapeutics (NASDAQ:LRMR) Price Target to $15.00

June 26, 2025 | americanbankingnews.com

Equities Analysts Issue Forecasts for LRMR Q2 Earnings

June 25, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)

June 24, 2025 | theglobeandmail.com

Wedbush Issues Pessimistic Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price

June 24, 2025 | marketbeat.com

Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim

June 24, 2025 | marketbeat.com

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

June 23, 2025 | globenewswire.com

Larimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development Program

June 22, 2025 | nasdaq.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

June 20, 2025 | finance.yahoo.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

June 20, 2025 | globenewswire.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Update

June 16, 2025 | marketbeat.com

Millennium Management LLC Sells 508,912 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

June 6, 2025 | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Average Rating of "Buy" by Brokerages

June 6, 2025 | marketbeat.com

Deutsche Bank AG Sells 238,010 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

June 3, 2025 | marketbeat.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Short Interest Up 64.7% in May

June 1, 2025 | marketbeat.com

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR, GHRS, KURA, and CRMD Company Descriptions

CorMedix NASDAQ:CRMD

$12.50 -2.46 (-16.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.48 -0.02 (-0.12%)

As of 06/27/2025 07:59 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

GH Research NASDAQ:GHRS

$12.44 +0.04 (+0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$12.37 -0.07 (-0.56%)

As of 06/27/2025 04:04 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Kura Oncology NASDAQ:KURA

$5.67 -0.06 (-1.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.78 +0.11 (+1.94%)

As of 06/27/2025 06:33 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Larimar Therapeutics NASDAQ:LRMR

$3.03 -0.05 (-1.62%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.00 -0.03 (-1.16%)

As of 06/27/2025 07:55 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time